Company Overview
Cardiol Therapeutics Inc. operates as a clinical-stage life sciences company dedicated to developing anti-fibrotic and anti-inflammatory therapies specifically designed for the treatment of heart diseases. The company functions within the Healthcare sector, more specifically in the Drug Manufacturers - Specialty & Generic industry, a classification that denotes its focus on creating specialized pharmaceutical solutions rather than mass-market generic drugs. As of the latest available data, the entity maintains a market capitalization of $139.60M, employs 18 individuals, and reports no annual revenue figures in its trailing twelve-month period. The absence of reported revenue combined with a market cap of $139.60M indicates that the company is in an early-stage development phase where value is primarily derived from intellectual property and clinical trial progress rather than commercial sales volume. This scale, characterized by a small workforce and a lack of generated sales, reflects the typical profile of a pre-revenue biotechnology firm concentrating resources on advancing its lead product candidate, CardiolRx, through Phase III clinical trials.
Financial Health
The financial profile of Cardiol Therapeutics Inc. is defined by significant operating losses, with a net income of $-34,784,616 and an EBITDA of $-36,409,240 over the trailing twelve months. The substantial gap between the zero revenue and the negative net income reveals a cost structure driven entirely by research, development, and clinical trial expenses rather than cost of goods sold, which is typical for clinical-stage entities. The company generated a free cash flow of $-15,344,989, indicating a high burn rate that consumes cash reserves to fund ongoing operations and scientific advancement. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, a figure that signifies the company has not yet transitioned to a revenue-generating model where profitability can be measured against sales. On the balance sheet, the company holds $11.62M in cash against $134,199 in debt, resulting in a debt-to-equity ratio of 1.40, which suggests a leveraged position relative to equity but indicates manageable absolute debt levels given the cash on hand. The current ratio stands at 3.89, which indicates strong short-term liquidity relative to obligations, though this metric is less relevant for a pre-revenue company with minimal current liabilities. Return on Equity is -348.0% and Return on Assets is -148.8%, metrics that reveal management is utilizing shareholder capital and assets to generate losses rather than returns, a necessary condition for clinical-stage companies but one that signals a lack of immediate profitability or effective capital deployment in traditional terms.
Valuation Assessment
Valuation metrics for Cardiol Therapeutics Inc. reflect its status as a speculative asset with no earnings history, as evidenced by a trailing P/E ratio of N/A and a forward P/E of -4.77. The negative forward P/E implies that the market is pricing in continued losses or expects a significant turnaround in earnings trajectory before the stock can be valued on a traditional earnings basis. The price-to-book ratio is 15.89, indicating a substantial market premium over the company's book value, which suggests investors are valuing the company based on the potential value of its clinical pipeline and intellectual property rather than current tangible assets. Alternative valuation metrics such as the price-to-sales ratio of N/A and an EV/EBITDA of -2.69 further highlight the reliance on non-traditional valuation methods due to the lack of revenue and earnings. The stock has traded between a 52-week high of $1.59 and a 52-week low of $0.77, meaning the current price sits at a position relative to this range that reflects ongoing volatility typical of small-cap biotech firms. The beta value of 0.73 indicates that the stock exhibits lower price volatility relative to the broader market, suggesting it may move less aggressively than the overall equity index despite its high-risk profile.
Growth & Income
The revenue growth and earnings growth rates are both listed as N/A, as the company has not generated sufficient revenue to calculate year-over-year growth percentages. The absence of positive earnings growth relative to revenue is inherent to the business model, as the company is reinvesting all available capital into R&D rather than generating profit. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, meaning it does not distribute cash to shareholders but instead retains earnings to fund its clinical trials and operational costs. This reinvestment strategy is standard for clinical-stage life sciences companies, where growth is pursued through the advancement of product candidates like CardiolRx rather than through dividend distributions. The overall growth and income profile is characterized by a complete lack of current financial returns, with the entire corporate focus directed toward achieving regulatory approval and commercializing its lead product to unlock future value creation.